Table 4. Univariate and multivariate analyses to predict progression free survival.
| Variables | Univariate | Multivariate | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Gender | 0.867 (0.111–6.793) | 0.892 | – | – | |
| Male | |||||
| Female | |||||
| Age (years) | 1.006 (0.960–1.553) | 0.807 | – | – | |
| IMDC | 0.041 (0.004–0.468) | 0.01 | 0.077 (0.007–0.914) | 0.042 | |
| Low risk | |||||
| Intermediate risk | |||||
| High risk | |||||
| Metastatic sites | – | – | |||
| Lung | 1.897 (0.626–5.752) | 0.258 | – | – | |
| Bone | 2.359 (0.797–6.981) | 0.121 | – | – | |
| Lymph nodes | 1.150 (0.317–4.176) | 0.832 | – | – | |
| Others | 0.996 (0.271–3.661) | 0.995 | – | – | |
| Surgery | 4.102 (1.270–13.248) | 0.018 | 3.327 (0.948–11.667) | 0.061 | |
| Yes | |||||
No
IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; HR, hazards ratio; CI, confidence interval.